United States · Platforms & data · The Motley Fool

AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue?

Published by The Motley Fool · United States 2 h ago

AbbVie's revenue lead has widened to $4 billion per quarter, but Bristol Myers shows surprising resilience despite slower growth.

Read the full article on The Motley Fool Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.fool.com)

Also worth reading

Time for a Micron mindset shift? Here’s how to navigate the new AI landscape.

Strategy Inc Variable Rate Series A Perpetual Stretch Preferred Stock (NASDAQ:STRC) Declares Dividend Increase - $0.04 Per Share

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Medical Properties earnings in focus as turnaround test looms

Walmart launches new membership deal, offers nearly $100 in savings

Nvidia’s Jensen Huang Sees 100GW AI Opportunity In Telecom Networks, With TMUS, NOK Already Making Moves